• China NT Pharma completed a debt-to-equity loan capitalisation on Sept. 4, issuing 847,565,892 new shares at HK$ 0.37.
• Issued share count rose to 1,796,563,586; new shares represented about 47.18% of the enlarged share capital.
• First Subscriber stake increased to 42.12% from 32.03%, becoming the largest shareholder.
• Public shareholding fell to 28.87% from 46.71% following the issuance.
• Mr. Ieong Iat’s stake diluted to 8.16% from 15.44%; Second Subscriber rose to 13.97% from 0.02%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China NT Pharma Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260904-12321678), on September 04, 2026, and is solely responsible for the information contained therein.